



THE UNIVERSITY
of ADELAIDE



APICOMPLEXAN VACCINE

A non-live vaccine for the prevention of Apicomplexan parasitic diseases and other pathogens

Benefits

- Non-live vaccine.
- Longer shelf life than live vaccines.
- Easier to store and import.

Background

Apicomplexan parasites are responsible for some of the most serious, debilitating and economically important diseases of humans and animals, including Coccidiosis, Toxoplasmosis and Neosporosis.

The vaccines that have reached the market against a few of the Apicomplexan diseases use live organisms, that are fraught with problems including limited shelf life, logistics, storage, importation, and reversion to virulence. A non-live vaccine would remove many of these problems.

Technology overview

We have developed a method of producing a non-live vaccine that has the potential to treat diseases caused by Apicomplexan parasites.

Vaccines for the bovine market are most advanced.

A study using pregnant ewes demonstrated that the novel Apicomplexan vaccine was efficacious in the protection of ewes from *T. gondii* associated abortion. The vaccine significantly reduced the number of abortions in ewes and significantly increased the number of viable lambs born following challenge in a *T. gondii* ovine infection model.



Opportunity

We are seeking a development partner, commercial partner, or financial investment.

IP status

The invention is subject to provisional patent applications therefore details of the invention are currently subject to confidentiality requirements.

Inventors

[Assoc Prof Ryan O'Handley](#)

Commercial contact

[Francois Duvenage](#)

Commercial Manager

E: francois.duvenage@adelaide.edu.au

FURTHER ENQUIRIES

Innovation and Commercial Partners
The University of Adelaide SA 5005 Australia

ENQUIRIES +61 8 8313 1336

adelaide.edu.au/icp

twitter.com/UoA_Innovation

[linkedin.com/company/innovationcommercial](https://www.linkedin.com/company/innovationcommercial)

Outfit Job No: 1924496 CRICOS 00123M

adelaide.edu.au/icp